menu
    • menu
    [{"orgOrder":0,"company":"Redx Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RXC004","moa":"Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RXC004","moa":"Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Simbec-Orion","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Simbec-Orion","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Simbec-Orion"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denosumab","moa":"||Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jounce Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"RXC007","moa":"ROCK2","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Jounce Therapeutics"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jounce Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"RXC007","moa":"ROCK2","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Jounce Therapeutics"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RXC004","moa":"Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Simbec Research","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Simbec Research","highestDevelopmentStatusID":"6","companyTruncated":"Redx Pharma \/ Simbec Research"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0.88,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.88,"dosageForm":"Undisclosed","sponsorNew":"Redx Pharma \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharma \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0.41999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Redx Pharma \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharma \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"RXC006","moa":"Protein-serine O-palmitoleoyltransferase porcupine (PORCN)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0.38,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"Redx Pharma \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharma \/ AstraZeneca"}]

    Find Clinical Drug Pipeline Developments & Deals by Redx Pharma

    Menu

    Redx Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $880.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Jazz Pharmaceuticals Enters Agreement with Redx to Acquire KRAS Inhibitor Program

                            Details : Through the acquisition, Jazz Pharmaceuticals will have access to Redx Pharma KRAS inhibitor program for all clinical development, regulatory, manufacturing, and commercialization activities.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $10.0 million

                            July 02, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $880.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC007

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Redx Provides Progress Update on RXC007 Clinical Programm

                            Details : RXC007 is an oral, selective Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 02, 2023

                            Lead Product(s) : RXC007

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC007

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Jounce Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

                            Details : Under the termination, Jounce Therapeutics will not merge with Redx. The business combination was supposed to aim the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic ...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 04, 2023

                            Lead Product(s) : RXC007

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Jounce Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC007

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Jounce Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Redx and Jounce Announce Recommended Business Combination

                            Details : Through the business combination, the combined group's priority will be the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 23, 2023

                            Lead Product(s) : RXC007

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Jounce Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC007

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Simbec-Orion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : RXC007

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Simbec-Orion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC004,Denosumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Redx Announces First Patient Dosed in Phase 2 Clinical Trial of RXC004 in Patients with Advanced Colorectal Ca...

                            Details : A second arm of the trial, evaluating RXC004 in combination with the anti-PD-1 antibody nivolumab in patients with MSS mCRC, is expected to commence in the first half of 2022 once a recommended dose has been established in the ongoing Phase 1 dose escala...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 15, 2021

                            Lead Product(s) : RXC004,Denosumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC007

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Simbec Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy V...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 18, 2021

                            Lead Product(s) : RXC007

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Simbec Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Redx Pharma

                            United Kingdom arrow
                            NASP
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            NASP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC004

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therap...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 01, 2021

                            Lead Product(s) : RXC004

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC004

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberr...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 28, 2021

                            Lead Product(s) : RXC004

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Redx Pharma

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $420.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Redx Announces New Research Collaboration with Jazz Pharmaceuticals to Discover and Develop Two Targeted Cance...

                            Details : Under the terms of the collaboration agreement, Redx will be responsible for research and preclinical development activities up to Investigational New Drug (IND) submission.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $10.0 million

                            September 09, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $420.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth